Pazopanib eye drops: A randomised trial in neovascular age-related macular degeneration

British Journal of Ophthalmology

Volumn 98, Issue 2, 2014, Pages 172-178

  Danis, Ronald ^a   McLaughlin, Megan M ^b   Tolentino, Michael ^c   Staurenghi, Giovanni ^d   Ye, Li ^b   Xu, Chun Fang ^e   Kim, Robert Y ^b   Johnson, Mark W ^f  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Center for Retina and Macular Disease   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

CLINICAL TRIAL; DIAGNOSTIC TESTS/INVESTIGATION; DRUGS; MACULA; NEOVASCULARISATION;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84892614334     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303117     Document Type: Article

References (27)

1. Fine FL, Berger JW, Macguire MG, et al. Age-related macular degeneration. N Engl J Med 2000; 342: 483-92. (Pubitemid 30100237)
2. Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011; 151: 887-95.
3. Food and Drug Administration. FDA labeling information. FDA website [online]. http: //www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 125156s053lbl.pdf (accessed Jan 2013).
4. Food and Drug Administration. FDA labeling information. FDA website [online]. http: //www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 125387s004lbl.pdf (accessed Jan 2013).
5. Edwards AO, Ritter R III, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4. (Pubitemid 40530082)
6. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9. (Pubitemid 40530070)
7. Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci 2009; 50: 2044-53.
8. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006; 38: 1055-59. (Pubitemid 44325932)
9. Swaroop A, Chew EY, Richman CB, et al. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Ann Rev Genomics Hum Genet 2009; 10: 19-43.
10. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114: 2168-73. (Pubitemid 350181136)
11. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011; 89: e344-9.
12. Teper SJ, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010; 16: 2598-604.
13. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011; 52: 4694-702.
14. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009; 93: 610-13.
15. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96: 208-12.
16. Orlin A, Hadley D, Chang W, et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012; 32: 4-9.
17. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6: 2012-21. (Pubitemid 47052491)
18. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8.
19. van Der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib in metastatic soft tissue sarcoma (PALETTE): a randomized, double-blind, placebo controlled phase trial. Lancet 2012; 379: 1879-86.
20. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006; 168: 2036-53. (Pubitemid 43825322)
21. Takahashi K, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009; 127: 494-9.
22. Yafai Y, Yang XM, Niemeyer M, et al. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol 2011; 666: 12-18.
23. Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 1868-75.
24. Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012; 119: 2304-11.
25. Food and Drug Administration. FDA labeling information. FDA website [online]. http: //www.accessdata.fda.gov/drugsatfda-docs/label/2009/022465lbl. pdf (accessed Nov 2012).
26. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 2006; 15: 2784-90. (Pubitemid 44400405)
27. Kondo N, Bessho H, Honda S, et al. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2011; 118: 339-44.